Unknown

Dataset Information

0

In vitro/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin/PBLG-PEG-PBLG nanoparticles.


ABSTRACT:

Background

The objective of this study was to survey the therapeutic function of curcumin-encapsulated poly(gamma-benzyl l-glutamate)-poly(ethylene glycol)-poly(gammabenzyl l-glutamate) (PBLG-PEG-PBLG) (P) on diabetic cardiomyopathy (DCM) via cross regulation effect of calcium-sensing receptor (CaSR) and endogenous cystathionine-γ-lyase (CSE)/hydrogen sulfide (H2S).

Methods

Diabetic rats were preconditioned with 20 mg/kg curcumin or curcumin/P complex continuously for 8 weeks. The blood and myocardiums were collected, the level of serum H2S was observed, and the [Ca2+]i content was measured in myocardial cells, and hematoxylin-eosin, CaSR, CSE, and calmodulin (CaM) expression were detected.

Results

Both curcumin and curcumin/P pretreatment alleviated pathological morphological damage of myocardium, increased H2S and [Ca2+]i levels, and upregulated the expression of CaSR, CSE, and CaM as compared to DCM group, while curcumin/P remarkably augmented this effect.

Conclusion

PBLG-PEG-PBLG could improve water-solubility and bioactivity of curcumin and curcumin/PBLG-PEG-PBLG significantly alleviated diabetic cardiomyopathy.

SUBMITTER: Tong F 

PROVIDER: S-EPMC5892954 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6251318 | biostudies-literature
| S-EPMC4636738 | biostudies-literature
| S-EPMC3245330 | biostudies-literature
| S-EPMC2860962 | biostudies-literature
| S-EPMC5654819 | biostudies-literature
| S-EPMC8241168 | biostudies-literature
| S-EPMC6058614 | biostudies-literature
| S-EPMC3418179 | biostudies-literature
| S-EPMC6836764 | biostudies-literature
| S-EPMC6168007 | biostudies-literature